Novel Fused Pyrimidines as Potent Cyclin‐Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies

ABSTRACT Our research aims to design novel pyrimidine derivatives inspired by the common pyrimidine core found in many FDA‐approved drugs. However, extensive prior research on the pyrimidine scaffold has made discovering new molecules more challenging. To overcome this obstacle, we employed a molecu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chemical biology & drug design 2024-11, Vol.104 (5), p.e70013-n/a
Hauptverfasser: Saravanakumar, Natarajan, Poorani, Arunagiri Sivanesan Aruna, Dhanabalan, Anantha Krishnan, Sugapriya, Selvam, Kumaresan, Ganesan, Suresh, Palaniswamy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Our research aims to design novel pyrimidine derivatives inspired by the common pyrimidine core found in many FDA‐approved drugs. However, extensive prior research on the pyrimidine scaffold has made discovering new molecules more challenging. To overcome this obstacle, we employed a molecular hybridisation strategy, opting to hybridise tetralin and pyrimidine, recognising their potential in cancer therapeutics. The fused pyrimidine was synthesised through a base‐mediated condensation of chalcone with amidine. The reaction conditions were further optimised for base, solvent, temperature and time to produce a series of 21 novel derivatives. These compounds were subsequently screened for anticancer activity against gastric adenocarcinoma cell lines using the MTT assay. Among the synthesised compounds, 2‐(pyridin‐3‐yl)‐4‐(pyridin‐3‐yl)‐5,6‐dihydrobenzo[h]quinazoline 8b and 4‐(2‐(pyridin‐3‐yl)‐5,6 dihydrobenzo[h]quinazolin‐4‐yl) phenol 5g exhibited potent anticancer activity compared to (R)‐Roscovitine. Additionally, a molecular docking study was conducted to assess the reactivity of compound 5g, revealing that the presence of a phenolic hydroxyl group enables hydrogen bonding with CDKs and enhances anticancer activity. Furthermore, the efficacy of compound 5g was validated through an in vitro CDK2/cyclin A2 enzyme inhibition assay. Interestingly, the observed CDK2 inhibitory activity showed a good correlation with the corresponding value for the antiproliferative activity of the tested compounds. A series of novel fused pyrimidine derivatives are designed and synthesised, and their anticancer activity is subsequently screened against gastric adenocarcinoma cell lines using the MTT assay. A docking study was conducted and validated with CDK enzyme inhibition activity, providing robust support for the anticancer activity of this synthesised compound. Compound 4‐(2‐(pyridin‐3‐yl)‐5,6‐dihydrobenzo[h]quinazolin‐4‐yl) phenol exhibited potent anticancer activity.
ISSN:1747-0277
1747-0285
1747-0285
DOI:10.1111/cbdd.70013